The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

The following is a summary of “Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study,” published in the January 2025 issue of Cardiology by ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...